Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen


Mendel A., Bernatsky S., Pineau C. A., St-Pierre Y., HANLY J. G., Urowitz M. B., ...More

RHEUMATOLOGY, vol.58, no.7, pp.1259-1267, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 58 Issue: 7
  • Publication Date: 2019
  • Doi Number: 10.1093/rheumatology/kez014
  • Journal Name: RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1259-1267
  • Keywords: systemic lupus erythematosus, anti-phospholipid syndrome, contraception, epidemiology, COMBINED ORAL-CONTRACEPTIVES, VENOUS THROMBOSIS, ANTIPHOSPHOLIPID ANTIBODIES, NEUROPSYCHIATRIC EVENTS, PREGNANCY OUTCOMES, RISK, DIAGNOSIS, CRITERIA, CLASSIFICATION, CANCER
  • Istanbul University Affiliated: Yes

Abstract

Objectives To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.